Science Consulting Services

In the past 24 months, I’ve worked with multiple medical device companies to successfully secure FDA clearance achieving a 𝗳𝗶𝗿𝘀𝘁-𝘁𝗶𝗺𝗲 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗿𝗮𝘁𝗲 𝗼𝗳 𝟴𝟳%, significantly higher than the industry average of ~45% The key? Prioritizing 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁 𝗼𝘃𝗲𝗿 𝘀𝗽𝗲𝗲𝗱-𝘁𝗼-𝗺𝗮𝗿𝗸𝗲𝘁 in regulatory strategy. Here are 7 counterintuitive lessons we've learned: 1. 𝗧𝗵𝗲 𝗳𝗮𝘀𝘁𝗲𝘀𝘁 𝗽𝗮𝘁𝗵 𝗶𝘀𝗻’𝘁 𝗮𝗹𝘄𝗮𝘆𝘀 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗹𝗲 • One client pivoted from 510(k) to De Novo, extending the timeline by 4.7 months but increasing the valuation • Another saved 9 months by narrowing initial claims based on available clinical data, then expanded in Year 2    2. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁 𝗱𝗿𝗶𝘃𝗲𝘀 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝗰𝗲 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝘀𝗽𝗲𝗲𝗱 • Companies with stronger clinical validation raised 𝟮.𝟯𝘅 𝗺𝗼𝗿𝗲 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 (Series B, 2022-2023) • Clients who invested in robust clinical evidence saw 𝟰𝟭% 𝗵𝗶𝗴𝗵𝗲𝗿 𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻𝘀 3. 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝘀𝗵𝗼𝘂𝗹𝗱 𝘀𝘁𝗮𝗿𝘁 𝗮𝘁 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗰𝗼𝗻𝗰𝗲𝗽𝘁𝗶𝗼𝗻 • Emergency remediation clients often fail due to late regulatory planning • Teams integrating regulatory experts from day one were 𝟯𝘅 𝗺𝗼𝗿𝗲 𝗹𝗶𝗸𝗲𝗹𝘆 𝘁𝗼 𝗮𝗰𝗵𝗶𝗲𝘃𝗲 𝗳𝗶𝗿𝘀𝘁-𝗿𝗼𝘂𝗻𝗱 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 4. 𝗠𝗮𝗿𝗸𝗲𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 𝘃𝗮𝗿𝗶𝗲𝘀 𝗱𝗿𝗮𝗺𝗮𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗯𝘆 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 • Cardiovascular reimbursement pathways took 𝟭𝟭.𝟯 𝗺𝗼𝗻𝘁𝗵𝘀 𝗹𝗼𝗻𝗴𝗲𝗿 than orthopaedics • Neurological devices faced 2𝘅 𝗺𝗼𝗿𝗲 𝗽𝗼𝘀𝘁-𝗺𝗮𝗿𝗸𝗲𝘁 𝘀𝘂𝗿𝘃𝗲𝗶𝗹𝗹𝗮𝗻𝗰𝗲 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 5. 𝗣𝗿𝗲𝗱𝗶𝗰𝗮𝘁𝗲 𝗱𝗲𝘃𝗶𝗰𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗶𝘀 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰, 𝗻𝗼𝘁 𝗷𝘂𝘀𝘁 𝘁𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 • Using multiple predicates increased review time by 𝟯𝟳% but expanded marketable indications by 𝟰𝟬% • One client’s strategic predicate choice avoided clinical requirements that would have added 𝟭𝟰 𝗺𝗼𝗻𝘁𝗵𝘀 6. 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝘀𝗵𝗼𝘂𝗹𝗱 𝘀𝗰𝗮𝗹𝗲 𝘄𝗶𝘁𝗵 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 • Companies with immature QMS faced 𝟮𝘅 𝗺𝗼𝗿𝗲 𝗱𝗲𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗹𝗲𝘁𝘁𝗲𝗿𝘀 • A staged QMS approach reduced the initial documentation burden by 61% for startups • eQMS platforms lowered maintenance costs by 𝟰𝟯% while improving compliance 7. 𝗚𝗹𝗼𝗯𝗮𝗹 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝘀 𝗺𝗮𝗿𝗸𝗲𝘁-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 • Simultaneous FDA/EU submissions succeeded only 𝟮𝟵% of the time under MDR • A sequential approach (FDA → EU) yielded 𝟳𝟰% 𝗳𝗮𝘀𝘁𝗲𝗿 total time to dual-market access 𝗧𝗔𝗞𝗘𝗔𝗪𝗔𝗬: 𝗧𝗵𝗲 𝗺𝗼𝘀𝘁 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗱𝗼𝗻’𝘁 𝗰𝗵𝗮𝘀𝗲 𝘁𝗵𝗲 𝗳𝗮𝘀𝘁𝗲𝘀𝘁 𝗽𝗮𝘁𝗵𝘄𝗮𝘆 𝘁𝗵𝗲𝘆 𝗽𝘂𝗿𝘀𝘂𝗲 𝘁𝗵𝗲 𝗼𝗻𝗲 𝘁𝗵𝗮𝘁 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗲𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁 𝗮𝗻𝗱 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗺𝗮𝗿𝗸𝗲𝘁 𝘀𝘂𝗰𝗰𝗲𝘀𝘀

10 point checklist for statistical planning and analysis! Do you agree? 1️⃣ Definition of the endpoints/outcome Was the study question clearly formulated (hypotheses) and the associated endpoints defined? Is the data suitable to answer the study question, or is it possible to collect suitable data prospectively? 2️⃣ Study design Has the study design been determined, i.e., is it a cross-sectional study, a case-control study, a cohort study, a randomized controlled trial (RCT), etc.? 3️⃣ Existing or planned number of cases Was an adequate sample size/power calculation conducted based on the information already available? 4️⃣ Missing and implausible values Has the handling of missing and implausible values been taken into account? Have methodical strategies been established to deal with or replace these values? 5️⃣ Distributions of the variables Has the distribution of the variables been checked for the available data? 6️⃣ Significance level and multiple testing If multiple tests will be carried out, have methods for adjusting the significance level been taken into account? 7️⃣ Selection of statistical tests and models Were the statistical tests and models selected and implemented to match the hypotheses? 8️⃣ Adjustment for confounders Were possible confounders or covariates statistically taken into account? 9️⃣ Interpretation of the results Has the correct interpretation of the results been made based on the statistical methods? 1️⃣0️⃣ Presentation of the results as text, table and figures Has the ideal form been selected from the various display options in text and table form? Were the results presented adequately graphically? What else would you add? #statistics #checklist

Navigating the complexities of #DrugDiscovery has always presented significant challenges, particularly in understanding protein-protein interactions. The introduction of PIONEER (Protein-protein InteractiOn iNtErfacE pRediction), a groundbreaking software developed by researchers at Cleveland Clinic and Cornell University, could be a game changer in our field. By integrating vast genomic data with physical protein structures, PIONEER offers an unprecedented tool for pinpointing crucial interaction points that can be targeted for effective treatments, especially for diseases like cancer. This innovative AI-driven approach not only streamlines the identification of potential drug targets but also addresses the longstanding bottlenecks in drug development timelines. The validation of this tool through extensive laboratory research underscores its potential to impact patient outcomes significantly. As we move forward, I believe tools like these will not only enhance our understanding of complex diseases but also expedite the path to delivering effective treatments to patients in need.

MDR/IVDR Are Just the Tip of Your Regulatory Iceberg—Look Beyond Them A cornerstone of successful medical device development is identifying all regulatory requirements. The MDR (Regulation (EU) 2017/745) and IVDR (Regulation (EU) 2017/746) provide a vast catalog of device requirements and company procedures. Standards then offer additional details for compliance. However, many see this as the entire iceberg and assume it’s enough for full compliance. The reality is different. Medical devices and manufacturers often need to comply with multiple regulations. It’s crucial to identify all applicable regulations beyond the obvious ones. Here are 7 regulations and directives many miss but are often essential: EU AI Act (Proposal COM/2021/206) → Crucial for any medical device incorporating AI. → Adds a certification framework beyond MDR/IVDR. → Overlapping requirements mean a thorough gap analysis is essential. European Health Data Space Regulation (Proposal COM/2022/197) → Central to unlocking cross-border health data sharing in the EU. → A framework for primary and secondary use of electronic health data. → Compliance requires alignment with GDPR and national health laws. Radio Equipment Directive (2014/53/EU) → Applies to devices with wireless communication (e.g., Bluetooth). → EMC testing under MDR isn’t enough for compliance. → Requires additional IFU content, such as wireless frequency specifications. General Data Protection Regulation (Regulation (EU) 2016/679) → Applies to all devices interacting with personal data. → Covers even non-sensitive data, beyond health-related information. → Expected since its enforcement began in 2018. Battery Regulation (Proposal COM/2020/798) → Relevant for devices with rechargeable or disposable batteries. → Mandates user access to batteries for removal or replacement. → Requires compliance with labeling and recycling standards. RoHS (Directive 2011/65/EU) and REACH (Regulation (EC) No 1907/2006) → Limit hazardous substances in device materials. → Biocompatibility doesn’t guarantee compliance with these regulations. → Crucial during material selection for physical devices. WEEE (Directive 2012/19/EU) → Governs proper decommissioning and disposal of electrical devices. → Includes exemptions for implantable and potentially infectious devices. → Often Requires agreements with waste management organizations. By identifying them early, the iceberg may remain large, but at least you’ll have transparency and control. P.S. What other regulations or directives would you add to this list? ⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡ MedTech regulatory challenges can be complex, but smart strategies, cutting-edge tools, and expert insights can make all the difference. I’m Tibor, passionate about leveraging AI to transform how regulatory processes are automated and managed. Let’s connect and collaborate to streamline regulatory work for everyone! #automation #regulatoryaffairs #medicaldevices

AI just designed a clinically effective antibiotic that works against MRSA. Most generative models in drug discovery propose molecules that can’t be synthesized or validated. That’s changing. 𝗦𝘆𝗻𝘁𝗵𝗲𝗠𝗼𝗹-𝗥𝗟 𝗶𝘀 𝗮 𝗿𝗲𝗶𝗻𝗳𝗼𝗿𝗰𝗲𝗺𝗲𝗻𝘁 𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗻𝗼𝘃𝗲𝗹, 𝘀𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝘁𝗿𝗮𝗰𝘁𝗮𝗯𝗹𝗲 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰𝘀 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲.  1. Searched a 46B compound space using RL to optimize antibacterial activity and solubility simultaneously.  2. Outperformed Monte Carlo and virtual screening baselines, generating 11.6% predicted multi-objective hits vs 0.006% for AI-based screening.  3. Synthesized 79 unique AI-designed compounds; 13 showed in vitro potency (MIC ≤ 8 µg/ml), and 7 were structurally novel.  4. Validated one compound, synthecin, in a mouse MRSA wound model, showing full infection suppression and zero tissue inflammation. Couple thoughts:  • Rather than filtering out high-toxicity candidates post-hoc via ADMET-AI, integrating ClinTox predictions into the RL reward could steer generation away from unsafe chemotypes from the outset.  • Feeding back in vitro MIC and solubility results to continuously retrain the RL value models could sharpen predictions in relevant chemical neighborhoods and expedite SAR optimization, leveraging the strong clustering behavior already observed.  • The current maximal independent set method ensures chemical diversity but can be further enhanced by recent GFlowNet-inspired subset selection algorithms to yield larger, more evenly distributed clusters of candidates. Here's the awesome work: https://lnkd.in/gwVNdtqy Congrats to Kyle Swanson, Gary Liu, Denise Catacutan, Stewart McLellan, Autumn Arnold, Jonathan M. Stokes, James Zou and co! I post my takes on the latest developments in health AI – 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝗺𝗲 𝘁𝗼 𝘀𝘁𝗮𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝗱! Also, check out my health AI blog here: https://lnkd.in/g3nrQFxW

📢 A new paper suggests that a plain-language text prompt may soon be enough to launch an end-to-end drug discovery program... In a new paper, co-authored by Alex Zhavoronkov and David Gennert, PhD, (Insilico Medicine) and Jiye Shi (Eli Lilly and Company), researchers conceptualize a drug discovery paradigm in which a text prompt can initiate an end-to-end drug development program, from target discovery to a clinical-ready candidate. In "From Prompt to Drug: Toward Pharmaceutical Superintelligence", the authors describe how modern drug discovery already can benefit from AI at nearly every step, including omics-driven target identification, generative molecular design, docking and ADMET prediction, retrosynthesis planning, automated synthesis, and even clinical trial modeling. ☝ The problem, they argue, is not a lack of capability but a lack of integration. These systems operate in silos, with humans coordinating handoffs between tools, labs, and teams, creating delays, errors, and bias. Their proposed solution is an AI-orchestrated "system-of-systems". Large language models with advanced reasoning capabilities act as central controllers: planning workflows, coordinating specialized AI agents, calling physics-based models (molecular dynamics, docking, QM), and interfacing with automated laboratories via APIs. Rather than generating molecules directly and hoping for the best, the system runs closed-loop design–make–test–analyze cycles, where experimental results continuously feed back into model refinement. The paper is explicit about technical constraints, though. LLMs alone lack biochemical grounding, suffer from hallucinations, and can propagate errors across pipeline stages. To mitigate this, the authors emphasize hybrid architectures combining language-based planning with structure-aware models, ensemble validation between agents, confidence propagation, backtracking, and mandatory human-in-the-loop checkpoints for high-stakes decisions such as clinical trial design. They refer to the long-term outcome as Pharmaceutical Superintelligence. It is not a single model, but a coordinated, multimodal platform trained on omics data, molecular structures, experimental results, and clinical outcomes, capable of autonomously running large portions of drug discovery while remaining auditable and regulator-aligned. It is a thought-provoking read, and I am curious to read your thoughts about it. While the idea might seem futuristic to some, Insilico Medicine demonstrated a track record of fast-paced drug discovery programs reaching clinical milestones... so while none of their programs are FDA approved yet, they are certainly trying hard to build this vision, it seems... time will tell. Image credit: authors of the paper

Clinical Evaluation: Guidance That Can Actually Help, and what's coming 📣   When it comes to building a Clinical Evaluation Report (CER), the challenge is not just finding data, but understanding how to structure it, appraise it, and explain why it matters, in the right way.   There isn’t one single rulebook. But there are guidance documents that many clinical and regulatory teams find genuinely helpful for meeting the expectations:   🧭 𝗠𝗘𝗗𝗗𝗘𝗩 𝟮.𝟳/𝟭 𝗥𝗲𝘃. 𝟰 Still a core reference under MDR for CER methodology and structure.   📄 𝗠𝗗𝗖𝗚 𝟮𝟬𝟮𝟬-𝟭𝟯 Provides clear insight into what Notified Bodies are looking for.   📄 𝗠𝗗𝗖𝗚 𝟮𝟬𝟮𝟬-𝟲 Focuses on clinical evidence needed for legacy devices.   🌐 𝗜𝗠𝗗𝗥𝗙 𝗠𝗗𝗖𝗘 𝗪𝗚/𝗡𝟱𝟲 Global, international guidance for clinical evaluation and appraisal approach.   📄 𝗧𝗚𝗔 – 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 (𝘃𝟯.𝟮) A practical, structured overview and guidance for sources of clinical data and evaluation steps.   💻 𝗠𝗗𝗖𝗚 𝟮𝟬𝟮𝟬-𝟭 Clinical & performance evaluation of medical device software (MDSW)   💻 𝗜𝗠𝗗𝗥𝗙 𝗦𝗮𝗠𝗗 𝗪𝗚/𝗡𝟰𝟭 Clinical evaluation principles specific to Software as a Medical Device (SaMD)   🇸🇬 𝗛𝗦𝗔 𝗚𝗡-𝟮𝟬 (𝗦𝗶𝗻𝗴𝗮𝗽𝗼𝗿𝗲) Clinical evaluation guidance for consultation.   📣 Keep an eye on what is on the way:   📄 𝗠𝗗𝗖𝗚-𝗖𝗜𝗘 → A new upcoming guidance document → Revision of MEDDEV 2.7/1 Rev. 4 → Adaptation to MDR   📘 𝗜𝗦𝗢 𝟭𝟴𝟵𝟲𝟵 → A new standard for clinical evaluation of medical devices → Will include detailed instructions and templates → To support MDR harmonization ✅ Now approaching the Draft International Standard (DIS) stage after last week’s working group meeting.   Using the right guidance won’t do the work for you.
 But it will help you build a stronger, more review-ready process. Being up to date on the latest guidance versions and new relevant document is crucial to ensure alignment with authorities and their expectations.   👉 Which guideline do you rely on most in your clinical evaluation process?   #MedBoard #ClinicalEvaluation #CER #MDR #MDCG #ISO18969 #TGA #MEDDEV #ClinicalAffairs #RegulatoryAffairs #MedTech

Very excited to share a new paper that has been a long time in the making. This has been a fun collaboration with my co-authors Ruoxuan Xiong (Emory) and Alex Chin (my co-worker at Lyft and now Motif Analytics). Randomized experiments are the gold standard for measuring causal effects, but in marketplaces we are often testing policies that have many plausible spillovers that make it difficult to learn what we need by assigning treatment across users. Instead we randomize over time. This type of experiment seems simple to design, you are implementing a square wave (a type of oscillator) that determines what policy you are running based on time. When I was at Lyft, we had some heuristics for choosing switchback parameters but we rarely had bandwidth to understand their impact. It turns out to be a rich design space, and by choosing how and when you switch policies, you control the bias and variance of the estimates from your experiment. Intuitively, faster switching yields lower variance by increasing your sample size but increases bias because effects tend to persist over time (carryover effects). Your measurements from each time period are also correlated and have heteroskedastic errors due to seasonality (marketplaces tend to have strong daily and weekly cycles). Our approach is effectively a model-based design process where we use historical data to estimate the inputs to the experimental design process. The data allow us to make informed decisions about switching behavior that will yield the lowest error in our estimates. Carryover effects are the hardest quantity to estimate from historical data because on any individual test they are quite noisy, so pooling is necessary to gain some additional precision. We analyze a corpus of hundreds of switchback tests from Lyft's marketplace, and cluster them into an interpretable distribution over impulse responses. A broader point of this research is that all experimental designs lean on prior knowledge to improve the chances of a successful experiment -- even choosing a sample size for desired power in a standard A/B test. In switchback tests, there is an important bias-variance tradeoff we must manage. Without some means to estimate the covariance of errors and the likely size and shape of carryover effects, it is difficult to design an experiment that is likely to be successful.

🔥 The best A/B testing textbook isn't a book at all If you are tired of generic courses, "expert" threads, or dense textbooks, there is a powerful source of knowledge you are likely overlooking. The most effective way to learn experimentation is from the people who build the platforms that run them. Beyond blogs and talks, these teams publish something far more valuable: their product documentation. These docs often describe in great detail: - Concrete approaches to experiment analysis. - The exact statistical methods used by top tech companies. - Formulas you can directly implement in your own workflow. I genuinely think this is one of the best ways to learn. Here are three platforms I recommend starting with: ⚫ Statsig - https://lnkd.in/dpdGE7u7 They offer incredible depth on scaling experiments. Start here: - Calculating sample size when using CUPED: https://lnkd.in/dkcQGRuZ - Advanced experimentation techniques: https://lnkd.in/d_W_sKXR ⚫ Eppo - https://lnkd.in/dH--rvKG A great resource for modern statistical approaches. Check out: - Their documentation on core methodologies: https://lnkd.in/dzWN8mMw - Their breakdown of Bayesian vs Frequentist approaches: https://lnkd.in/dPhHZCfR ⚫ Optimizely - https://lnkd.in/d9RvbbxV The industry standard for a reason. Their library is vast: - Practical ideas for conversion rate optimization: https://lnkd.in/d-jmw4AF - Sample size calculations unpacked: https://lnkd.in/d3PFjdDr ⚫ Hidden gem - The Open Guide to Successful AB Testing by GrowthBook https://lnkd.in/d9nm-VEC Stop looking for the perfect course and start reading the docs. You will find more practical value there than in almost any "how to" guide.

As academics, we all want our research to be trusted, reproducible, and strong enough to withstand review. Yet most of the problems we face during publication come from one place: weak statistical foundations and unclear experimental design. This is why I want to give you a quick, practical guide you can use to strengthen any study you are planning or refining. These principles are simple, but they prevent the most common errors I see across manuscripts, reviews, and collaborations. 1. Statistics is not about numbers. It is about reasoning. Each test, each calculation, tells a story about your data and what it truly means. 2. Experimental design begins with purpose. Define your objective clearly before you begin collecting data. The design should flow naturally from the research question. 3. Randomization protects integrity. Assign treatments randomly to eliminate bias and ensure valid comparisons. 4. Replication increases confidence. Repeating experiments strengthens conclusions and helps distinguish real effects from noise. 5. Control groups matter. They provide the baseline that gives your results meaning. Without controls, interpretation becomes speculation. 6. Choose tests based on data, not habit. Understand whether your variables are categorical, continuous, or ordinal. Then select the statistical method that fits the data, not the one that feels familiar. 7. Interpret, do not just report. Numbers are not the end of the story. Explain what they mean, why they matter, and how they support or challenge your hypothesis. 8. Visuals clarify understanding. Use tables and graphs to reveal patterns and relationships, but keep them clean, accurate, and purposeful. 9. Ethical analysis is non-negotiable. Never manipulate data to fit a narrative. Transparency and honesty sustain the credibility of your research. 10. Statistics and design are partners. Good design minimizes errors. Good statistics reveal the truth within them. One without the other cannot stand. These principles are not theoretical. They are the difference between a study that moves quickly through review and a study that struggles with rejection, uncertainty, or inconsistent conclusions. Download the full PDF below. Do you think your current research would benefit from this guide? Reply and tell me. I would love to know. ______________________________ 📌 This is Prof. Samira Hosseini. I’ve helped 12,000+ ambitious academics go from struggling with publishing papers in Q1 journals, limited visibility, and poor citation records to building a solid research trajectory and high 𝘩-index. Book a free Strategy Call, and we can dive into your challenges in top-tier journal publication and citation and see how I can best assist you: https://lnkd.in/ezqV64dX